

RMD Open
Rheumatic & Musculoskeletal Disease

Supplemental Table 1

Correlations between Fatigue Numeric Rating Scale score and other outcomes at baseline and weeks 12 and 24, intent-to-treat population, last observation carried forward^a

	SPIRIT-P1			SPIRIT-P2		
	Time Point	Pearson Correlation (95% CI)	Level of Correlation ^b	Time Point	Pearson Correlation (95% CI)	Level of Correlation ^b
mCPDAI	Baseline	0.29 (0.19, 0.37)	Fair	Baseline	0.31 (0.22, 0.40)	Fair
	Week 12	0.28 (0.10, 0.45)	Fair	Week 12	0.51 (0.43, 0.59)	Moderate
	Week 24	0.48 (0.39, 0.55)	Moderate	Week 24	0.53 (0.45, 0.61)	Moderate
SF-36 Role Emotional	Baseline	-0.43 (-0.50, -0.34)	Moderate	Baseline	-0.42 (-0.51, -0.33)	Moderate
	Week 12	-0.43 (-0.50, -0.35)	Moderate	Week 12	-0.40 (-0.48, -0.31)	Fair/Moderate
	Week 24	-0.43 (-0.50, -0.34)	Moderate	Week 24	-0.47 (-0.55, -0.39)	Moderate
SF-36 Social Functioning	Baseline	-0.47 (-0.54, -0.39)	Moderate	Baseline	-0.52 (-0.59, -0.44)	Moderate
	Week 12	-0.54 (-0.61, -0.47)	Moderate	Week 12	-0.58 (-0.64, -0.51)	Moderate
	Week 24	-0.54 (-0.60, -0.46)	Moderate	Week 24	-0.59 (-0.65, -0.52)	Moderate

RMD Open
Rheumatic & Musculoskeletal Disease

		SPIRIT-P1		SPIRIT-P2		
DAPSA	Baseline	0.31 (0.22, 0.39)	Fair	Baseline	0.40 (0.31, 0.48)	Fair/Moderate
	Week 12	0.55 (0.48, 0.61)	Moderate	Week 12	0.48 (0.40, 0.56)	Moderate
	Week 24	0.54 (0.47, 0.61)	Moderate	Week 24	0.47 (0.39, 0.55)	Moderate
SF-36 Role Physical	Baseline	-0.51 (-0.58, -0.43)	Moderate	Baseline	-0.56 (-0.63, -0.49)	Moderate
	Week 12	-0.58 (-0.64, -0.51)	Moderate	Week 12	-0.61 (-0.67, -0.54)	Substantial
	Week 24	-0.59 (-0.65, -0.52)	Moderate	Week 24	-0.62 (-0.68, -0.55)	Substantial
SF-36 Physical Functioning	Baseline	-0.56 (-0.63, -0.49)	Moderate	Baseline	-0.52 (-0.59, -0.44)	Moderate
	Week 12	-0.61 (-0.67, -0.55)	Substantial	Week 12	-0.61 (-0.67, -0.54)	Substantial
	Week 24	-0.60 (-0.66, -0.53)	Moderate/ Substantial	Week 24	-0.61 (-0.67, -0.54)	Substantial
HAQ-DI	Baseline	0.61 (0.55, 0.67)	Substantial	Baseline	0.51 (0.43, 0.58)	Moderate
	Week 12	0.62 (0.56, 0.68)	Substantial	Week 12	0.61 (0.54, 0.67)	Substantial
	Week 24	0.61 (0.54, 0.66)	Substantial	Week 24	0.64 (0.57, 0.69)	Substantial

RMD Open
Rheumatic & Musculoskeletal Disease

		SPIRIT-P1		SPIRIT-P2		
PGA	Baseline	0.46 (0.38, 0.53)	Moderate	Baseline	0.34 (0.25, 0.43)	Fair
	Week 12	0.64 (0.58, 0.70)	Substantial	Week 12	0.61 (0.54, 0.67)	Substantial
	Week 24	0.64 (0.58, 0.70)	Substantial	Week 24	0.67 (0.61, 0.72)	Substantial
PASDAS	Baseline	0.50 (0.42, 0.57)	Moderate	Baseline	0.44 (0.35, 0.53)	Moderate
	Week 12	0.64 (0.58, 0.70)	Substantial	Week 12	0.62 (0.55, 0.68)	Substantial
	Week 24	0.65 (0.59, 0.71)	Substantial	Week 24	0.66 (0.59, 0.71)	Substantial
Joint Pain	Baseline	0.50 (0.42, 0.57)	Moderate	Baseline	0.47 (0.39, 0.55)	Moderate
	Week 12	0.65 (0.59, 0.71)	Substantial	Week 12	0.67 (0.61, 0.72)	Substantial
	Week 24	0.66 (0.60, 0.71)	Substantial	Week 24	0.69 (0.63, 0.74)	Substantial
SF-36 Vitality Domain	Baseline	-0.63 (-0.69, -0.57)	Substantial	Baseline	-0.64 (-0.70, -0.57)	Substantial
	Week 12	-0.66 (-0.71, -0.60)	Substantial	Week 12	-0.75 (-0.79, -0.70)	Substantial
	Week 24	-0.71 (-0.75, -0.66)	Substantial	Week 24	-0.76 (-0.80, -0.72)	Substantial

^aAnalysis conducted on pooled cohort data within each trial. Missing data at weeks 12 and 24 were imputed using last observation carried forward analysis.

^bAccording to Sackett's conventions: Poor [0.0–0.2], Fair [0.2–0.4], Moderate [0.4–0.6], Substantial [0.6–0.8], and Excellent [0.8–1.0].

RMD Open
Rheumatic & Musculoskeletal Disease

CI: confidence interval; DAPSA: Disease Activity Index for Psoriatic Arthritis; HAQ-DI: Health Assessment Questionnaire-Disability Index;

mCPDAI: Modified Composite Psoriatic Disease Activity Index; PGA: Patient Global Assessment; SF-36: Short-Form 36.